The ratings of six Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
SIGA Technologies’ (NASDAQ:SIGA) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. SIGA Technologies is a bio-defense company engaged in the discovery, development and commercialization of products for use in defense against biological warfare agents such as smallpox and arenaviruses. As of Dec. 12, 2012, 12.2% of outstanding SIGA Technologies shares were held short. For a full analysis of SIGA stock, visit Portfolio Grader.
This is a rough week for Spectrum Pharmaceuticals (NASDAQ:SPPI). The company’s rating falls to D from the previous week’s C. Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. As of Dec. 12, 2012, 49.5% of outstanding Spectrum Pharmaceuticals shares were held short. For more information, get Portfolio Grader’s complete analysis of SPPI stock.
Progenics Pharmaceuticals (NASDAQ:PGNX) earns a D this week, falling from last week’s grade of C. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. In Earnings Momentum, Earnings Revisions, Equity, and Sales Growth the stock gets F’s. For a full analysis of PGNX stock, visit Portfolio Grader.
Oncothyreon (NASDAQ:ONTY) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Oncothyreon is a biotechnology company that develops therapeutic approaches to cancer management. The stock gets F’s in Earnings Growth and Equity. The stock price has fallen 13.2% over the past month, worse than the 4.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ONTY stock.
This week, ArQule’s (NASDAQ:ARQL) rating worsens to an F from the company’s D rating a week ago. ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. The stock also rates an F in Sales Growth. To get an in-depth look at ARQL, get Portfolio Grader’s complete analysis of ARQL stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) experiences a ratings drop this week, going from last week’s D to an F. AMAG Pharmaceuticals utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of AMAG stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.